The Journal of Emergency Medicine
Volume 37, Issue 4 , Pages 396-399 , November 2009

Pattern of Orlistat Exposures in Children Aged 5 Years Or Less

  • Mathias B. Forrester, BS

      Affiliations

    • Corresponding Author InformationReprint Address: Mathias B. Forrester, bs, Epidemiology and Disease Surveillance Unit, Texas Department of State Health Services, 1100 W 49th Street, Austin, TX 78756

Received 6 November 2006 ,Revised 10 April 2007 ,Accepted 30 October 2007.

References 

  1. Complete product information (Xenical® (orlistat) capsules). Nutley, NJ: Roche Laboratories, Inc; 2005;http://www.rocheusa.com/products/xenical/pi.pdf. Accessed October 10, 2006
  2. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142:532–546
  3. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160–167
  4. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999;69:1108–1116
  5. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293:2873–2883
  6. Norgren S, Danielsson P, Jurold R, Lotborn M, Marcus C. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr. 2003;92:666–670

 Funding for this research was provided by a contract with the Commission on State Emergency Communications in Texas.

PII: S0736-4679(07)00910-9

doi: 10.1016/j.jemermed.2007.10.052

The Journal of Emergency Medicine
Volume 37, Issue 4 , Pages 396-399 , November 2009

Article Tools